Brokers Set Expectations for Portage Biotech Q1 Earnings

Portage Biotech Inc. (NASDAQ:ALP) – Research analysts at HC Wainwright issued their Q1 2028 earnings per share (EPS) estimates for shares of Portage Biotech in a report released on Monday, August 17th. HC Wainwright analyst M. Colonnese forecasts that the company will post earnings per share of ($0.04) for the quarter. HC Wainwright currently has a “Neutral” rating and a $0.25 target price on the stock. HC Wainwright also issued estimates for Portage Biotech’s Q2 2028 earnings at ($0.04) EPS, Q3 2028 earnings at ($0.04) EPS, Q4 2028 earnings at ($0.04) EPS and FY2028 earnings at ($0.17) EPS.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Portage Biotech presently has a consensus rating of “Reduce” and an average price target of $0.25.

Portage Biotech Stock Performance

Shares of Portage Biotech stock opened at $0.16 on Tuesday. The company has a market capitalization of $3.72 million, a PE ratio of -0.02 and a beta of 0.61. The company has a 50-day simple moving average of $0.29 and a two-hundred day simple moving average of $0.35. Portage Biotech has a one year low of $0.15 and a one year high of $13.80. The company has a debt-to-equity ratio of 0.01, a quick ratio of 0.31 and a current ratio of 0.31.

Portage Biotech (NASDAQ:ALP) last issued its quarterly earnings data on Thursday, July 16th. The company reported $0.48 earnings per share for the quarter. The company had revenue of $0.05 million for the quarter.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.